Impact of chronic wounds of various etiology on systemic profiles of key inflammatory cytokines, chemokines, and growth factors and their interplay

Małgorzata Krzystek-Korpacka1A−F, Krzysztof Kędzior1C,E,F, Leszek Masłowski2A,B,E,F, Magdalena Mierzchała2C−F, Iwona Bednarz-Misa1C,D,F, Agnieszka Bronowicka-Szydelko1B,E,F, Joanna Kubiak2B,E,F, Małgorzata Gacka1B,E,F, Sylwia Placzkowska1A,C,E,F, Andrzej Gamian1A,E,F

1 Department of Medical Biochemistry, Faculty of Medicine, Wrocław Medical University, Poland
2 Department of Angiology, Regional Specialist Hospital, Wrocław, Poland
3 Department of Angiology, Hypertension and Diabetes, Wrocław Medical University, Poland
4 Department of Professional Training in Clinical Chemistry, Wrocław Medical University, Poland

A – research concept and design; B – collection and/or assembly of data; C – data analysis and interpretation; D – writing the article; E – critical revision of the article; F – final approval of the article

Address for correspondence
Malgorzata Krzystek-Korpacka
E-mail: malgorzata.krzystek-korpacka@umed.wroc.pl

Funding sources
Statutory funding of Wrocław Medical University KST-911.

Conflict of interest
None declared

Acknowledgements
The authors would like to thank the Foundation of Wrocław Medical University (FAM) and its Board Chairmen for financing a lease of the BioPlex 200 platform.

Received on July 28, 2018
Reviewed on September 15, 2018
Accepted on February 8, 2019
Published online on August 19, 2019

Abstract

Background. Non-healing wounds are becoming a growing concern for public health as a result of their increasing prevalence in progressively aging societies.

Objectives. The aim of this article is to evaluate the effects of wound etiology on a panel of circulating cytokines in patients with non-healing wounds of the lower extremities.

Material and methods. This prospective case-control study involved 104 individuals: healthy elderly people (n = 46) and patients with diabetes and/or cardiovascular disease (n = 58; among them 38 with chronic wounds of venous, ischemic or neurotrophic etiology). Selected serum cytokines – i.e. IL-1β, IL-4, IL-6, IL-8, FGF-2, G-CSF, GM-CSF, MCP-1, MIP-1α, TNF-α, VEGF-A, and PDGF-BB – were measured using the Luminex platform.

Results. Compared to healthy elderly people, presence of diabetes and/or cardiovascular disease was associated with elevated IL-6, IL-8, MCP-1 and G-CSF while non-healing wounds coexisted with the increase in the levels of all examined cytokines/growth factors except for G-CSF and GM-CSF. Among diseased elderly people, having wounds was associated with increased levels of IL-1β, IL-4, IL-6, IL-8, FGF-2, G-CSF, GM-CSF, MCP-1, MIP-1α, TNF-α, VEGF-A, and PDGF-BB – were measured using the Luminex platform.

Conclusions. The results presented herein may improve our understanding of the pathomechanisms which lead to chronic wounds and of the effects they exert on a systemic level, as well as providing potential targets for more effective therapies.
Introduction

Conditions such as diabetes or atherosclerosis can disturb blood flow, damage blood vessels, and, if severe, result in ulcerations or gangrene, most often located in the lower limbs. Moreover, together with age and obesity, they are listed as key factors which adversely affect proper wound healing. Taking into account the prevalence of obesity, diabetes and cardiovascular disease among elderly people, chronic wounds of the lower extremities are becoming a growing socioeconomic problem for aging societies. Persistent, frequent and often infected, they reduce quality of life, rendering afflicted persons disabled and in need of repeated hospitalization.\textsuperscript{1,2} Non-healing wounds are a major cause of morbidity and mortality and are responsible for over 80% of diabetes-associated amputations.\textsuperscript{3,4} Chronic wounds are currently estimated to affect up to 2% of the general population but – because their prevalence is increasing – it is predicted that they will affect \( \frac{1}{4} \) of elderly people by the year 2050.\textsuperscript{5}

While the proper healing of an injury requires a sequence of events, tightly orchestrated in time and space by a plethora of humoral mediators, chronic wounds are believed to be locked in the initial inflammatory phase without resolution.\textsuperscript{4} A deregulated cytokine and growth factor network which promotes an inflammatory response but causes aberrations in immune cell recruitment, shifts in the proteolytic balance and impaired formation of blood vessels is implicated in the pathogenesis of chronic wounds.\textsuperscript{6} So far, most of the attention has been focused on profiling cytokines and growth factors in wound fluids and biopsies, as they are believed to reflect the microenvironment of non-healing wounds best, whereas the pathogenic significance of the accompanying systemic inflammation has received little attention.\textsuperscript{7} However, alterations in local cytokine and growth factor concentrations are unlikely to contribute to the systemic effects of chronic wounds, such as considerably higher mortality rates.\textsuperscript{8,9} Also, the collection and analysis of wound exudates pose some technical and interpretational problems.\textsuperscript{10} Even more importantly, high proteolytic activity – a hallmark of non-healing wounds\textsuperscript{4} – is likely to falsify any results.

Thus, the purpose of our study was to profile, on a systemic level, the key pro-inflammatory and pro-angiogenic cytokines and growth factors and their interplay in healthy elderly people compared with seniors burdened with chronic conditions like diabetes and cardiovascular disease, either without or with complications in the form of chronic wounds. Also, we aimed to compare the cytokine profiles and correlation patterns in patients with chronic wounds, stratified by wound type and etiology.

Material and methods

Study population

The study population consisted of 104 individuals: 48 apparently healthy seniors and 56 elderly patients with diabetes and/or cardiovascular disease – 38 of whom had chronic wounds of the lower extremities. Patients with chronic wounds were recruited from the Department of Angiology of the Regional Specialist Hospital in Wroclaw, Poland. Only patients with chronic wounds in the course of cardiovascular disease or diabetes were included, while patients with non-healing wounds due to autoimmune diseases, malignancy, infections, or drugs were excluded. Wound etiology was determined by its characteristics (location and an appearance of the wound, its borders, and the surrounding skin, pain, and the presence of bleeding on manipulation) in conjunction with the patient’s history and clinical assessment based on the ankle–brachial pressure index, ultrasound, angiography, and computed tomography (CT), among other things. The wound etiology was determined to be as follows: venous stasis (\( n = 17 \)), ischemic (arterial) (\( n = 13 \)) and neurotrophic (\( n = 6 \)); in 2 cases, the dominant component was unclear (mixed ischemic/venous). Many of the patients (\( n = 27 \)) exclusively had ulcerations, 5 had ulcerations and gangrene, and 6 had gangrene alone. Of the 11 patients with gangrene, 6 had wet gangrene and 5 had dry gangrene. Phlegmons were present in 5 patients. Data on hematological (hemoglobin, Hb; white blood cells, WBC; and platelets, PLT), coagulation (activated partial thromboplastin time, APTT) and biochemical (high-sensitive C-reactive protein, hsCRP; and fibrinogen) indices were prospectively collected and measured according to standard procedures.

Twenty age-matched patients with a similar chronic disease burden (type 2 diabetes associated with hypertension, hyperlipidemia, micro- and/or macroangiopathy, ischemic heart disease, or peripheral artery occlusive disease) but no limb ulcerations were recruited from the Department of Angiology, Hypertension, and Diabetes of the Wroclaw Medical University as a reference. Age and sex-matched individuals with complaints of headaches and memory loss but without mild cognitive impairment or dementia and no other significant health history recruited from the Research, Science, and Educational Center of Dementia Diseases in Ścinawa, Poland served as an additional control group. The age distribution in these 3 groups was as follows: 68.3 ±12.2 years, 65.7 ±10.2 years and 64.4 ±9.8 years (\( p = 0.257 \)), respectively, while the female-to-male ratios were 17:21, 14:6 and 24:22 (\( p = 0.185 \)), respectively.

The study conforms to the ethical principles outlined in the Declaration of Helsinki. The study design was approved by the Medical Ethics Committees of Wroclaw Medical University and the Regional Specialist Hospital, and informed consent was obtained from the patients.
Analytical methods

Blood was drawn with venipuncture and was then clotted (30’) and centrifuged (15’, 720 x g). The resulting serum was frozen at –80°C until examination. Cytokine profiling was conducted in duplicate with flow cytometry-based method using magnetic microspheres conjugated with monoclonal antibodies using a BioPlex 200 (Bio-Rad, Hercules, USA), according to the manufacturer’s instructions, incorporating Luminex xMAP® technology and validated customplexes allowing for simultaneous measurement of interleukin (IL)-1β, IL-4, IL-6, IL-8, fibroblast growth factor (FGF)-2, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, tumor necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF)-A, and platelet-derived growth factor (PDGF)-BB. Standard curves were drawn using 4- or 5-parameter logistic (PL) regression and the data was analyzed using BioPlex Manager v. 6.0 software (BioRad).

Statistical analysis

The data distribution was tested with the Kolmogorov–Smirnov test and equality of variances was tested using Levene’s test. Intergroup differences were analyzed using one-way analysis of variance (ANOVA) and the t-test for independent samples with Welch correction, where appropriate, or the Kruskal–Wallis H test or Mann–Whitney U test. The data is presented as means or medians with a 95% confidence interval (CI). Frequency analysis was conducted using the χ² test. Patterns of univariate correlations were established using the Pearson or Spearman tests. For limited data sets, the Spearman test was applied, as it is less sensitive to outliers, and the results were additionally verified with the Kendall test. Logistic regression was conducted using the stepwise method with p = 0.05 and p = 0.1 as entrance and removal criteria. All calculated probabilities were two-tailed and p-values ≤0.05 were considered statistically significant. The analyses were performed using MedCalc® v. 14.10.2 (MedCalc Software, Mariakerke, Belgium) statistical software.

Results

Circulating cytokines in patients with chronic wounds and age-matched controls with or without comparable chronic disease burden

We compared the levels of circulating cytokines in patients with chronic wounds with those found in individuals with a comparable disease burden (cardiovascular disease or diabetes) but without chronic wounds, and with those of elderly people without significant medical history, who served as age-matched controls. Interleukin 6, IL-8, G-CSF, and MCP-1 were the only cytokines which were significantly higher in the patients without wounds than in the controls. In turn, compared to the healthy controls, the patients with chronic wounds had elevated levels of all cytokines apart from G-CSF and GM-CSF. The elevation of IL-1β, IL-4, IL-6, IL-8, FGF-2, MIP-1α, PDGF-BB, and VEGF-A was more accentuated in patients with chronic wounds than in patients with similar disease burden but no wounds (Table 1).

In a logistic regression analysis (stepwise method), an increase in IL-1β alone was an independent predictor

---

Table 1. Systemic levels of key inflammatory cytokines and growth factors in the study population

<table>
<thead>
<tr>
<th>Cytokine/growth factor</th>
<th>Patients with chronic wounds (W)</th>
<th>Diseased seniors (D)</th>
<th>Controls (C)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β [ng/L]</td>
<td>6.5 (5.4–8.3)D,C</td>
<td>0 (0.0–0.4)U</td>
<td>0 (0.0–0.4)nm</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>IL-4 [ng/L]</td>
<td>5.9 (4.7–7.7)D,C</td>
<td>1.5 (1.2–1.9)U</td>
<td>1.3 (1.2–1.9)D</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>IL-6 [ng/L]</td>
<td>23.3 (18.5–34.6)D,C</td>
<td>6.9 (5.3–10.1)L,C</td>
<td>4.6 (3.7–5.0)D,D</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>IL-8 [ng/L]</td>
<td>139.6 (97.6–173.7)D,C</td>
<td>16.6 (11.4–24.1)L,C</td>
<td>10.7 (9.2–13.5)D,D</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>FGF2 [ng/L]</td>
<td>32.1 (28.3–34.4)D,C</td>
<td>4.3 (0.2–6.3)L</td>
<td>4.1 (2.7–11.3)D,D</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>G-CSF [ng/L]</td>
<td>24.3 (21.3–27.7)C</td>
<td>32.7 (25.4–43.1)L,C</td>
<td>21.2 (17.8–25.3)D,D</td>
<td>0.009A</td>
</tr>
<tr>
<td>GM-CSF [ng/L]</td>
<td>13.8 (11.0–18.4)C</td>
<td>11.3 (7.0–22.7)</td>
<td>15.2 (11.7–19.4)</td>
<td>0.961K</td>
</tr>
<tr>
<td>MCP-1 [ng/L]</td>
<td>70.2 (59.6–82.7)F</td>
<td>66.8 (53.4–83.6)L,C</td>
<td>38.5 (30.9–48.9)D,D</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>MIP-1α [ng/L]</td>
<td>11.1 (7.7–13.6)E,C</td>
<td>1.4 (0.6–1.9)U</td>
<td>1.7 (1.1–2.4)D</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>PDGF-BB [µg/L]</td>
<td>3.6 (2.6–4.5)C</td>
<td>2.1 (1.7–2.8)U</td>
<td>1.72 (1.4–2.1)D</td>
<td>&lt;0.001K</td>
</tr>
<tr>
<td>TNF-α [ng/L]</td>
<td>14.6 (11.0–16.8)F</td>
<td>12.9 (9.4–15.3)</td>
<td>10.6 (7.8–14.1)D</td>
<td>0.031F</td>
</tr>
<tr>
<td>VEGF-A [ng/L]</td>
<td>3.28 (170.4–478.4)D,C</td>
<td>50.1 (26.2–88.2)L,U</td>
<td>46.6 (37.4–58.7)nm</td>
<td>&lt;0.001K</td>
</tr>
</tbody>
</table>

Data is presented as means or medians with a 95% confidence interval (CI) and was analyzed with one-way ANOVA or the Kruskal–Wallis H test. D – significantly different from diseased seniors without chronic wounds; W – significantly different from patients with chronic wounds; C – significantly different from apparently healthy age-matched controls; K – Kruskal–Wallis H test; A – one-way ANOVA; IL - interleukin; FGF2 – fibroblast growth factor 2; G-CSF – granulocyte colony-stimulating factor; GM-CSF – granulocyte-macrophage colony-stimulating factor; MCP-1 – monocyte chemoattractant protein-1; MIP-1α – macrophage inflammatory protein-1α; PDGF-BB – platelet-derived growth factor BB; TNF-α – tumor necrosis factor α; VEGF-A – vascular endothelial growth factor A.
of the presence of chronic wounds (b = 1.84, const. –5.26; p < 0.0001) with an OR of 6.32 (95% CI = 2.6–15.6), correctly classifying 99% of cases with an area under the curve (AUC) = 0.995 (0.96–1.0).

Correlations of circulating cytokines and growth factors with laboratory parameters in patients with chronic wounds

Although there was no direct correlation with hemoglobin concentration, circulating IL-8 was significantly higher in the patients with hypochromia (137.6 pg/mL (107–168) vs 212.5 pg/mL (163–263), p = 0.007) and MIP-1α (12.2 pg/mL (10.2–14.3) vs 15.1 pg/mL (12.7–17.4), p = 0.061), IL-6 (23.3 pg/mL (17.9–47.6) vs 42.2 pg/mL (26.5–133.2), p = 0.071), and VEGF-A (332 pg/mL (133–694) vs 614 pg/mL (326–1278), p = 0.087) tended to be higher as well. MCP-1 (r = −0.5, p = 0.036) and PDGF-BB (r = −0.48, p = 0.042) were inversely correlated with activated partial thromboplastin time, an indicator of the efficacy of coagulation pathways, and a similar tendency was observed for IL-4 (r = −0.46, p = 0.056).

Apart from IL-6 (r = 0.49, p = 0.009, n = 27), none of the studied cytokines and growth factors correlated with CRP. However, there were significant positive correlations with fibrinogen: TNF-α (r = 0.52, p = 0.012), IL-1β (r = 0.48, p = 0.021), IL-6 (r = 0.45, p = 0.032), GM-CSF (r = 0.47, p = 0.023), G-CSF (r = 0.46, p = 0.029), and FGF-2 (r = 0.38, p = 0.073). The same held true for WBC count: TNF-α (r = 0.57, p = 0.002), MIP-1α (r = 0.42, p = 0.031), IL-4 (r = 0.46, p = 0.016), IL-1β (r = 0.54, p = 0.004), IL-6 (r = 0.38, p = 0.050), IL-8 (r = 0.47, p = 0.014), GM-CSF (r = 0.60, p < 0.001), G-CSF (r = 0.56, p = 0.002), and FGF-2 (r = 0.57, p = 0.002). Likewise, positive correlations were
found between fibrinogen and PLT count: TNF-α (r = 0.44, p = 0.021), MIP-1α (r = 0.52, p = 0.006), IL-4 (r = 0.38, p = 0.048), IL-1β (r = 0.43, p = 0.025), IL-8 (r = 0.53, p = 0.004), GM-CSF (r = 0.45, p = 0.018), and G-CSF (r = 0.39, p = 0.044).

**Correlations of circulating cytokines and growth factors with wound type**

There were tendencies towards more accentuated elevations of IL-6, IL-8, MIP-1α, and VEGF-A levels (p = 0.145, p = 0.186, p = 0.137, and p = 0.169, respectively) in patients with both gangrene and ulcerations compared to those with ulcerations alone. There were no significant differences in circulating cytokines or growth factors in terms of the type of gangrene (wet vs dry) or the presence of phlegmon.

**Correlations of circulating cytokines and growth factors with wound etiology**

When stratified by wound etiology, there were significantly higher levels of IL-1β, IL-4, IL-8, FGF-2, G-CSF, GM-CSF, PDGF-BB, and TNF-α in patients with neurotrophic wounds than with ischemic ones. Interleukin 6 displayed a similar tendency. G-CSF and IL-6 were significantly higher in neurotrophic wounds than venous ones as well (Fig. 1).

Moreover, G-CSF levels in patients with ischemic (p = 0.015) and venous (p = 0.025) wounds were significantly lower than in individuals with a similar burden of chronic diseases but no wounds. While IL-1β, IL-4, IL-6, IL-8, FGF-2, MIP-1α, and VEGF-A were significantly higher in patients with chronic wounds than in controls independent of their etiology, there were differences concerning PDGF-BB and TNF-α. The wound-associated elevation of PDGF-BB in these patients compared to ones with a similar disease burden was significant exclusively in neurotrophic wounds (p < 0.001; p = 0.061 for venous and p = 0.384 for ischemic). Compared to individuals without a significant medical history, there was no elevation of PDGF-BB in ischemic wounds (p = 0.131; p = 0.0001 for neurotrophic and p = 0.003 for venous). Tumor necrosis factor α was significantly higher in patients with neurotrophic wounds than in healthy controls (p = 0.013; p = 0.179 for ischemic and p = 0.089 for venous).

**Cytokine interplay**

The associations observed in the healthy elderly people were either nonexistent or less accentuated than those

### Table 2. Cytokine correlation pattern in the study population

<table>
<thead>
<tr>
<th>Cytokine/growth factor</th>
<th>FGF-2</th>
<th>G-CSF</th>
<th>GM-CSF</th>
<th>IL-1β</th>
<th>IL-4</th>
<th>IL-6</th>
<th>IL-8</th>
<th>MCP-1</th>
<th>MIP-1α</th>
<th>PDGF-BB</th>
<th>TNF-α</th>
<th>VEGF-A</th>
</tr>
</thead>
<tbody>
<tr>
<td>FGF-2</td>
<td>–</td>
<td>0.73*</td>
<td>0.73*</td>
<td>0.51*</td>
<td>0.70*</td>
<td></td>
<td></td>
<td>0.29*</td>
<td></td>
<td></td>
<td>0.39*</td>
<td></td>
</tr>
<tr>
<td>G-CSF</td>
<td>0.84*</td>
<td>–</td>
<td>0.49*</td>
<td>0.56*</td>
<td>0.30*</td>
<td></td>
<td></td>
<td>0.35*</td>
<td>0.55*</td>
<td>0.32*</td>
<td>0.51*</td>
<td>0.54*</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>0.89*</td>
<td>0.92*</td>
<td>–</td>
<td>0.58*</td>
<td>0.30*</td>
<td></td>
<td></td>
<td></td>
<td>0.49*</td>
<td>0.55*</td>
<td>0.39*</td>
<td>0.46*</td>
</tr>
<tr>
<td>IL-1β</td>
<td>0.83*</td>
<td>0.97*</td>
<td>0.93*</td>
<td>–</td>
<td>0.56*</td>
<td>0.30*</td>
<td></td>
<td></td>
<td>0.48*</td>
<td>0.47*</td>
<td>0.44*</td>
<td>0.61*</td>
</tr>
<tr>
<td>IL-4</td>
<td>0.86*</td>
<td>0.91*</td>
<td>0.82*</td>
<td>0.54*</td>
<td>0.56*</td>
<td></td>
<td></td>
<td></td>
<td>0.56*</td>
<td>0.53*</td>
<td>0.61*</td>
<td>0.54*</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.42*</td>
<td>0.68*</td>
<td>0.55*</td>
<td>0.62*</td>
<td>0.62*</td>
<td></td>
<td></td>
<td></td>
<td>0.53*</td>
<td>0.54*</td>
<td>0.53*</td>
<td>0.74*</td>
</tr>
<tr>
<td>IL-8</td>
<td>0.58*</td>
<td>0.75*</td>
<td>0.61*</td>
<td>0.71*</td>
<td>0.76*</td>
<td>0.80*</td>
<td></td>
<td></td>
<td>0.36*</td>
<td>0.84*</td>
<td>0.36*</td>
<td>0.57*</td>
</tr>
<tr>
<td>MCP-1</td>
<td>0.39*</td>
<td>0.49*</td>
<td>0.50*</td>
<td>0.44*</td>
<td>0.43*</td>
<td>0.44*</td>
<td></td>
<td></td>
<td>0.84*</td>
<td>0.37*</td>
<td>0.53*</td>
<td>0.49*</td>
</tr>
<tr>
<td>MIP-1α</td>
<td>0.68*</td>
<td>0.78*</td>
<td>0.69*</td>
<td>0.77*</td>
<td>0.84*</td>
<td>0.69*</td>
<td>0.75*</td>
<td></td>
<td>0.37*</td>
<td>0.40*</td>
<td>0.37*</td>
<td>0.54*</td>
</tr>
<tr>
<td>PDGF-BB</td>
<td>0.88*</td>
<td>0.86*</td>
<td>0.89*</td>
<td>0.86*</td>
<td>0.55*</td>
<td>0.63*</td>
<td>0.47*</td>
<td></td>
<td>0.37*</td>
<td>0.40*</td>
<td>0.53*</td>
<td>0.62*</td>
</tr>
<tr>
<td>TNF-α</td>
<td>0.76*</td>
<td>0.85*</td>
<td>0.85*</td>
<td>0.75*</td>
<td>0.55*</td>
<td>0.54*</td>
<td>0.46*</td>
<td></td>
<td>0.01*</td>
<td>0.72*</td>
<td>0.53*</td>
<td>0.55*</td>
</tr>
<tr>
<td>VEGF-A</td>
<td>0.55*</td>
<td>0.69*</td>
<td>0.57*</td>
<td>0.64*</td>
<td>0.65*</td>
<td>0.77*</td>
<td>0.79*</td>
<td></td>
<td>0.53*</td>
<td>0.53*</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Unless otherwise indicated, data is presented as Pearson correlation coefficients. * – p < 0.05; † – p < 0.01; ‡ – p < 0.001; S – Spearman correlation coefficient; ns – not statistically significant. Correlations for the chronic wound group are presented on the left of the table. Correlations for the healthy elders are presented on the right of the table in regular font. Correlations for the diseased seniors without chronic wounds are presented on the right of the table in italic font.
in patients burdened with chronic diseases. Compared to patients with chronic wounds, there were no interrelationships for MCP-1 and only a few for IL-8, MIP-1α, PDGF-BB, and VEGF-A. In patients with chronic wounds, all cytokines were correlated and the statistical power of most of the observed associations was high (Table 2).

The analysis of patterns of cytokine correlation in patients with wounds stratified by wound etiology revealed a pattern of tight associations for venous wounds, while in ischemic wounds the associations were looser, even more so in neurotrophic wounds. The disruption of cytokine interrelationships in neurotrophic wounds was particularly evident for IL-6, IL-8, MCP-1, and VEGF-A – whose levels did not correlate with any other cytokine – and, to a lesser extent, for PDGF-BB and FGF-2 (Table 3).

**Discussion**

While there are number of studies which have profiled mediators of inflammation, angiogenesis and matrix remodeling in wound exudates, we focused on the levels of these mediators in circulation. The investigation of wound fluids is compelling, as it may potentially provide insight into what happens directly at the site of inflammation. However, due to the extremely high proteolytic activity which may falsly increase or decrease the availability of antigen epitopes for antibody-based assays or may cause artificial mass shifts in proteomic analyses, the examination of exudates may be equally misleading. It may account for reported increases in the levels of some cytokines with collection time and for a diminished ability of exudate to stimulate human dermal fibroblasts despite an elevated cytokine concentrations. Consequently, the results of such analyses are often contradictory, as exemplified by calcium-binding proteins S100A8 and A9, the deficiency and overexpression of which have both been named a hallmark of non-healing wounds. Moreover, circulating mediators can both regulate local processes over, circulating mediators can both regulate local processes and exert an effect systemically. As such, profiling them may help to reveal the mechanisms responsible for systemic events contributing to the considerably higher mortality rates of diabetics with ulcerations than those without wounds (R = 1.49) or of seniors with chronic wounds of various etiology compared to the age-matched general population (28 vs 4%).

Corroborating previous reports, all of our patients with diabetes and/or cardiovascular disease, regardless their wound status, had elevated levels of the cytokines characteristic of vascular inflammation and inflammatory milieu in diabetes: MCP-1, IL-6 and IL-8. MCP-1 is a key monocyte-attracting chemokine released from vascular endothelial cells (ECs) and smooth muscle cells (SMCs) during the initial phases of atherosclerosis. It facilitates trans-endothelial migration of adherent monocytes.
and induces EC and SMC migration as well as SMC proliferation.29

Circulating MCP-1 is believed to be a reliable marker of atherosclerotic plaque burden.20 As such, the equally high levels of MCP-1 in our diseased patients with and without chronic wounds confirms that both study groups were well-matched with respect to the degree of their affliction. Elevated MCP-1 in the serum of diabetic patients who developed foot ulcers has been predictive of healing failure.21

Interleukin 8, primarily a neutrophil-attracting chemokine, is involved in the induction of monocyte adhesion to the endothelium, the stimulation of SMC proliferation and migration, and – in later stages – in the enhancement of plaque angiogenesis.18 Interleukin 6, in turn, is one of the key leukocyte-derived pro-inflammatory cytokines which stimulates MCP-1 synthesis in macrophages and CRP expression in hepatocytes, as well as inducing SMC proliferation.22 However, inflammation is associated not only with the initiation of atherosclerosis, but also with its progression and the induction of plaque rupture.23 In this respect, it is interesting that the elevation of IL-6 and IL-8 levels was more accentuated in diseased seniors with wounds than in those without wounds (3.4-fold and 8.4-fold, respectively) and in diseased patients without wounds than in their healthy peers (1.5-fold). Interleukin 6, as well as IL-6-induced expression of CRP and MCP-1 in plaque macrophages, causes an overexpression of tissue factor (TF) and hence activates the pro-coagulant pathway. Accordingly, there was an adverse correlation between MCP-1 and APTT which, if shortened, might be indicative of an increased risk of thromboembolism. Also, IL-6 enhances the expression of matrix metalloproteinases (MMPs), facilitating the disintegration of fibrous caps, and thus destabilizing plaques.19,20 Similarly, IL-8 induces the endothelialial expression of MMP-2 and MMP-9 and inhibits the expression of their inhibitor, TIMP-1.20,21 As such, a more pronounced systemic elevation of these MMPs in combination with non-healing wounds promotes and sustains inflammatory milieu within blood vessels and may translate into the progression of atherosclerosis, plaque disruption and thrombosis. Accordingly, an elevation in circulating IL-818 or IL-6 level19,19 is an independent predictor of cardiovascular events in various clinical settings. Locally, such a substantial upregulation of circulating IL-6 and IL-8 may contribute to enhanced proteolytic activity and a degradation of growth factors within wounds, further disturbing their proper healing.

In addition to IL-6 and IL-8, IL-1β and MIP-1α were also more markedly upregulated in patients with chronic wounds. Interleukin 1β released from keratinocytes signals skin disruption, initiating and orchestrating the inflammatory response to injury.20 Accordingly, IL-1β alone was capable of correctly predicting the presence of wounds with 99% accuracy. Moreover, we observed a close correlation between IL-1β and all other evaluated cytokines and growth factors, which were either less accentuated or absent in individuals without chronic wounds. On the other hand, IL-1β is a pivotal activator of endothelial pro-coagulant activity and a suppressor of anticoagulant mechanisms, thereby contributing to microvascular thrombosis.22 Moreover, since lipid overload is one of the key factors contributing to plaque instability,23 the persistent upregulation of circulating IL-1β, an inhibitor of cholesterol efflux regulatory protein (CERP),27 may facilitate atheroma rupture as well. Increased plaque infiltration with T cells and macrophages is yet another indicator of plaque instability.23 In this respect, only in patients with diabetes/cardiovascular disease and chronic wounds, an 8-fold upregulation of circulating MIP-1α translates into accelerated migration of Th1 cells and cytotoxic CD8+ T lymphocytes into the inflamed vessels,28 the destabilization of existing atheromas, and – locally – the perpetuation and acceleration of inflammation within the wound. Indeed, an elevation in circulating MIP-1α has been associated with short-term mortality in patients with acute coronary syndrome.29

Several studies have shown lower levels of growth factors within chronic wounds than acute ones.26 However, notwithstanding reservations concerning the reliability of wound examinations, it has been suggested that chronic wounds might not necessarily be deficient in growth factors but that the growth factors might be inefficient, being trapped within the fibrin cuffs surrounding the capillaries.30 Undoubtedly, the high activity of wound proteases is likely to degrade both endogenous and exogenous growth factors, rendering them ineffective as well. Moreover, the deregulation of downstream events has been demonstrated and is likely to contribute.20 Accordingly, in our patients with chronic wounds, the levels of key circulating growth factors necessary for proper wound healing were significantly higher: FGF-2 (7-fold), PDGF-BB (1.7-fold) and VEGF-A (8-fold). Corroborating our observations, an elevation in FGF-2 and PDGF-AA but not VEGF-A was associated with a failure for diabetic foot ulcers to heal.21 As with pro-inflammatory cytokines, the persistent systemic upregulation of growth factors might be detrimental. In fact, FGF-2, through the upregulation of MMP-2 and MMP-9 expression and activity, contributes to the thinning of the fibrous cap of an atheroma.31 VEGF-A has been shown to prompt apoptosis in macrophages, a phenomenon which is critical for resolving inflammation in normal wound healing but which contributes to atheroma rupture if it affects plaque macrophages. Moreover, VEGF-A induces tissue factor expression in the endothelium, whereas PDGF-BB is responsible for vascular smooth muscle cells, monocytes and macrophages. This, in turn, initiates clotting cascade and thrombus formation on the one hand, and the proliferation and migration of vascular SMCs leading to plaque progression, destabilization and rupture on the other hand.33

Apart from creating a pro-coagulant environment which promotes arterial and venous thrombosis, persistently elevated levels of pro-inflammatory cytokines may
also contribute to the pathogenesis of anemia of chronic disease. Interleukin 6 plays a pivotal role in regulating levels of hepcidin, a major regulator of iron homeostasis. Additionally, pro-inflammatory cytokines directly affect erythropoiesis by inhibiting the synthesis of erythropoietin by or interfering with its signaling pathways. Accordingly, circulating IL-8 was significantly higher in patients with hypochromia, while IL-6, MIP-1α and VEGF-A displayed a similar tendency.

Data concerning an association of IL-4 with wound healing are scarce. Animal models show the involvement of IL-4 in normal wound healing, where it activates fibroblasts and stimulates the synthesis of extracellular matrix. Interleukin 4 is involved in the activation of macrophages into a wound-healing phenotype as well. However, IL-4 has also been demonstrated to hamper the proangiogenic capacity of macrophages by downregulating hypoxia-inducible factor (HIF)-1α translation. In vitro, stimulation with IL-4 reduced the migration of lung epithelial cells and hindered sinonasal epithelial wound closure. Corroborating the notion that IL-4 contributes to prolonged healing, circulating IL-4 was significantly upregulated in patients with non-healing wounds. While other Th2 cytokines display an anti-atherogenic effect, the role of IL-4 remains ambiguous but there are suggestions that it is a promoter of plaque progression. Supporting this concept, IL-4 in our patients positively correlated with WBC and PLT counts and inversely with APTT.

Contrary to other cytokines, the systemic levels of G-CSF and GM-CSF were not elevated in our patients. In fact, G-CSF levels in patients with wounds of ischemic or venous etiology were significantly lower. G-CSF is a hematopoietic cytokine which plays a crucial role in the host response to infection. It is responsible for increasing the number of neutrophils in circulation by stimulating the proliferation, survival and differentiation of their precursors as well as their release from blood marrow. It is also believed to display immunomodulatory and antibiotic-enhancing activities; exogenous G-CSF application has been found to be beneficial as well. Locally, insufficient levels of G-CSF in patients with chronic wounds may contribute to the ineffectiveness of neutrophils infiltrating the wound in fighting infection. Decreased systemic G-CSF concentrations may render patients with infected chronic wounds more susceptible to severe complications in a form of bacterial infection of the surrounding skin and bones – or even sepsis, if the infection spreads to the circulatory system. GM-CSF promotes healing through many mechanisms, e.g., by increasing VEGF expression in the ulcer bed and an increased healing of chronic leg ulcers treated with GM-CSF has been shown. Beidler et al. demonstrated that higher systemic levels of GM-CSF at presentation were predictive of faster healing venous ulcers following multilayer compression therapy.

As pointed out by Trostrup et al., the current knowledge on the differences or similarities between chronic wounds of various etiologies is insufficient, yet necessary to optimize treatment. To shed some light on the subject, we compared the profiles of circulating cytokines in patients stratified by wound etiology. Reflecting the prevalence in the general population, chronic wounds of venous etiology were the most common, whereas there were only a few cases of neurotrophic wounds in our study group. Nevertheless, neurotrophic wounds were associated with significantly higher levels of circulating IL-1β, IL-4, IL-8, FGF-2, G-CSF, GM-CSF, PDGF-BB, and TGF-α than ischemic wounds and higher levels of IL-6 and G-CSF than venous wounds.

Various cells involved in the tissue response to injury communicate through the cytokine network to orchestrate the event from inflammation induction to resolution and wound closure, making the proper interplay of cytokines critical. In addition to the differences in the systemic levels with respect to wound etiology, we observed a disruption of cytokine interrelationships in neurotrophic wounds. This was particularly evident for key inflammatory cytokines and chemokines – IL-6, IL-8 and MCP-1 – whose levels did not correlate with any other cytokine. The correlation pattern was also disrupted in the case of pro-angiogenic factors VEGF-A, PDGF-BB and FGF-2, supporting the notion that deregulation of their signaling and cross-talk plays a role in wound healing failure.

In conclusion, cytoprofiling revealed a pro-inflammatory state in patients with chronic wounds which might translate into enhanced pro-coagulant, pro-thrombotic and proteolytic activities that would locally contribute to prolonged healing or healing failure and – on a systemic level – may increase the risk of cardiovascular events and/or anemia of chronic disease. We also demonstrated that wound etiology affects the profile of circulating cytokines and growth factors as well as their interplay, altered particularly in patients with wounds of neurotrophic origin. Our findings may improve our understanding of the pathomechanisms leading to chronic wounds and the effects they exert on a systemic level, as well as providing potential targets for more effective therapies.

ORCID iDs
Malgorzata Krzęt-Korpacka https://orcid.org/0000-0002-2753-8092
Krzysztof Kędzior https://orcid.org/0000-0001-7206-8600
Leszek Masłowski: brak
Magdalena Mierzchała-Pasierb https://orcid.org/0000-0003-0674-429X
Iwona Bednarz-Miśa https://orcid.org/0000-0001-7244-2017
Agnieszka Bronowicka-Szydłko https://orcid.org/0000-0001-9967-036X
Joanna Kubiak: brak
Malgorzata Gacka https://orcid.org/0000-0001-5760-1534
Sylwia Placzewska https://orcid.org/0000-0002-1466-3820
Andrzej Gamian https://orcid.org/0000-0002-2206-6591

References
17. Souza JR, Oliveira RT, Blotta MH, Coelho OR. Serum levels of interleukin-6 (IL-6), interleukin-18 (IL-18) and C-reactive protein (CRP) in patients with type-2 diabetes and acute coronary syndrome without ST-segment elevation. Arq Bras Cardiol. 2008;90(2):86–90.